of isoniazid acetylation phenotype was carried out in 213 Japanese patients with pulmonary tuberculosis (control group) and 52 Japanese patients with both non-insulin-dependent diabetes mellitus and pulmonary tuberculosis (NIDDM group). 2.
On the other hand, polymorphic N-acetylation has recently been studied to detect relationships between an acetylator phenotype and the incidence of spontaneous disorders19). A predominance of slow acetylators has been shown in Gilbert's disease20) and in bladder cancer21); slow acetylation also appears to be more common in patients with gastric cancer22), rheumatoid arthritis23), and Sjogren's syndrome24). Conversely, rapid acetylator status has been reported to be predominate in patients with breast carcinoma25) and colorectal carcinoma26). An increased prevalence of rapid acetylators has also been described in patients of European origin with diabetes, both of the insulindependent (IDDM) and NIDDM types27). In Saudi Arabian patients, an association was found between the slow acetylator phenotype and IDDM. But, in other studies, phenotype frequencies in diabetic patients have not been significantly different from those in the normal population28). It is not known relationship between the acetylator phenotype and the incidence of diabetes mellitus in Japanese population groups.
The object of this investigation was to compare the distribution modes in Japanese for N-acetylation on NIDDM patients with pulmonary tuberculosis (TB) and pulmonary TB patients. After an overnight-fast, each patient emptied his bladder and was then given a single oral dose of INH at dose of 10mg/kg body weight. Urine samples were collected during the period 0 to 8hr postdose. Aliquots were forzen at -20C until analysis.
Method
INH and acetylisoniazid (AcINH) in urine were assayed by the HPLC method29). Among the several terms employed to express the activity of polymorphic hepatic N-acetyltransferase, the expression of phenotyping used the "molar acetylation ratio" {log (INH/AcINH)}.
Data Analysis
Frequency histograms and probit plots (cumulative frequency distribution) were constructed with data obtained from each calculation. Statistical significance was determined by the U-test of Mann-Whitney.
Results
The frequency histograms and probit plots of log (INH/AcINH) in Japanese control group and NIDDM group are shown in Fig. 1 and 2 . In the histogram of control group (A of Fig. 1 ), "the molar acetylation ratio" allowed a much wider range from 0.01 to 2.33, a 233-fold variation. In the histogram of NIDDM group (B of Fig. 1 ), "the molar acetylation ratio" allowed a wider range from 0.02 to 1.72, a 86-fold variation.
There were no significant difference between U-test of Mann-Whitney.
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